Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123554663 | 12355466 | 3 | F | 20160203 | 20160706 | 20160511 | 20160715 | EXP | US-NOVOPROD-490655 | NOVO NORDISK | 63.00 | YR | A | F | Y | 85.26000 | KG | 20160715 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123554663 | 12355466 | 1 | PS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | ONCE WEEKLY | Y | U | UNKNOWN | 22341 | SOLUTION FOR INJECTION | ||||||
| 123554663 | 12355466 | 2 | SS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | UNK MG, QD | Y | U | ES6V724 | 22341 | SOLUTION FOR INJECTION | QD | |||||
| 123554663 | 12355466 | 3 | SS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | UNK MG, QD | Y | U | ES6W0040 | 22341 | SOLUTION FOR INJECTION | QD | |||||
| 123554663 | 12355466 | 4 | C | NOVOLOG | INSULIN ASPART | 1 | Subcutaneous | UNKNOWN | UNKNOWN | 0 | SOLUTION FOR INJECTION | ||||||||
| 123554663 | 12355466 | 5 | C | LEVEMIR | INSULIN DETEMIR | 1 | Subcutaneous | UNKNOWN | UNKNOWN | 0 | SOLUTION FOR INJECTION | ||||||||
| 123554663 | 12355466 | 6 | C | LAMOTRIGINE. | LAMOTRIGINE | 1 | UNKNOWN | UNKNOWN | 0 | ||||||||||
| 123554663 | 12355466 | 7 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | UNKNOWN | UNKNOWN | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123554663 | 12355466 | 1 | Type 2 diabetes mellitus |
| 123554663 | 12355466 | 4 | Type 2 diabetes mellitus |
| 123554663 | 12355466 | 5 | Type 2 diabetes mellitus |
| 123554663 | 12355466 | 6 | Product used for unknown indication |
| 123554663 | 12355466 | 7 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123554663 | 12355466 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123554663 | 12355466 | Blood glucose increased | |
| 123554663 | 12355466 | Confusional state | |
| 123554663 | 12355466 | Dizziness | |
| 123554663 | 12355466 | Dysphemia | |
| 123554663 | 12355466 | Gait disturbance | |
| 123554663 | 12355466 | Generalised tonic-clonic seizure | |
| 123554663 | 12355466 | Laceration | |
| 123554663 | 12355466 | Nausea | |
| 123554663 | 12355466 | Off label use | |
| 123554663 | 12355466 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123554663 | 12355466 | 1 | 20160203 | 20160426 | 0 | |
| 123554663 | 12355466 | 2 | 20160427 | 20160502 | 0 | |
| 123554663 | 12355466 | 3 | 20160427 | 20160502 | 0 |